专著 （1）Luo Y., Wang D., Abbruzzese JL., Lu W. (2018) Pancreatic Cancer-Methods and Protocols. Measurement of Reactive Oxygen Species by Fluorescent Probes, in Pancreatic Cancer. Methods Mol Biol 1882:207-219. 3rd ed. Su GH, editor. Humana Press, Springer Nature, New York, NY. （2）McKeehan WL., Wang F., and Luo Y. (2010) The Fibroblast Growth Factor (FGF) Signaling Complex. In Ralph A. Bradshaw and Edward A. Dennis, editors: Handbook of Cell Signaling 2nd edition, Oxford: Academic Press. Chapter 46: 253-260 （3）Wang F., Luo Y., McKeehan WL. (2011) Chapter 6: The FGF Signaling Axis in Prostate Tumorigenesis. Molecular Oncology. 1st Ed., edited by E. Gelmann and C. Sawyers. Cambridge University Press, New York, NY 专利 （1）Wallace L. McKeehan, Yongde Luo. FGF affinity chromatography. U.S Patent #6,812,221, International patent #WO0242336 （2）Wallace L. McKeehan, Yongde Luo. Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor. WO Patent #WO2005079817 |
2.发表论文（具有代表性的5篇） （1）Luo Y., Yang Y., Liu M., et al., & Lu W. (2019) Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. Gastroenterology. 157(5):1413-1428.e11.
（2）Luo Y., Ye S., Li XK., Lu W. (2019) Emerging Structure-Function Paradigm of Endocrine FGFs in Metabolic Diseases. Trends Pharmacol Sci 40(2):142-153.
（3）Lu W., Li X., & Luo Y. (2021) FGF21 in Obesity and Cancer: New Insights. Cancer Lett. 499:5-13.
（4）Adams AC., Yang C., Coskun T., Cheng CC., Gimeno RE., Luo Y., Kharitonenkov A. (2013) The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2(1): 31-7. PMID: 24024127. （5）Ye M., Lu W., Wang X., Wang C., Abbruzzese J.L., Liang G., Li XK., Luo Y. (2016) FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function and ER stress in obesity. Endocrinology 157(12): 4754-69.
|
